Vaccine Knowledge Booster 2025: Evidence & Impact Webinar

September 17, 2025
Vaccines play a critical role in protecting individual and public health by preventing or reducing the severity of numerous infectious diseases. As vaccine technologies and immunologic strategies continue to advance, clinicians must stay informed to effectively communicate the benefits of vaccination, address patient concerns, and improve compliance.
 
Join our panel of vaccine experts as they explore the benefits of vaccination, assess the necessity of completing full vaccine series, and share best practices for managing non-compliant patients.
 
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Allergists, allied health and other allergy practitioners.

Learning Objectives

After completing this webinar, participants should be able to:
  1. Discuss the real-world impact of vaccines on public health and implement evidence-based strategies to counter misinformation in clinical practice.
  2. Interpret current data on vaccine schedules, including the clinical implications of incomplete versus full series completion for optimal immunity.
  3. Identify and apply best practices for evaluating and managing patients with suboptimal vaccine responses to vaccines such as COVID-19, MMR, Influenza, RSV, and Hepatitis B

      Additional information
      Disclosure: 
      As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

      Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:
      • Advertising, marketing, or communication firms whose clients are ineligible companies
      • Bio-medical startups that have begun a governmental regulatory approval process
      • Compounding pharmacies that manufacture proprietary compounds
      • Device manufacturers or distributors
      • Diagnostic labs that sell proprietary products
      • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
      • Manufacturers of health-related wearable products
      • Pharmaceutical companies or distributors
      • Pharmacy benefit managers
      • Reagent manufacturers or sellers
      The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

      Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

      Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.
      Course summary
      Available credit: 
      • 1.00 AMA PRA Category 1 Credit™
      • 1.00 Attendance
      • 1.00 CBRN
      Course opens: 
      09/17/2025
      Course expires: 
      12/31/2025
      Event starts: 
      09/17/2025 - 7:00pm CDT
      Event ends: 
      09/17/2025 - 8:00pm CDT
      Add to calendar: 
      Rating: 
      0
      S. Shahzad Mustafa, MD | is the division head of allergy, immunology, and rheumatology at Rochester Regional Health. In addition to seeing both pediatric and adult patients, Dr. Mustafa participates in clinical research, with a special interest in quality-of-life considerations in food allergies, and secondary immunodeficiency due to malignancy and chemotherapeutics. In hopes of optimizing the patient’s experience, Dr. Mustafa focuses on quality initiatives and improving systems of healthcare delivery.
      Disclosures: Speaker - AstraZeneca, CSL Behring, Genentech, GlaxoSmithKline, Regeneron 
       
      Deepa Patadia, MD | is Staff at Cleveland Clinic in the Department of Allergy and Clinical Immunology.  She is also Associate Program Director of the Allergy/Immunology Fellowship Program.  She completed residency in Internal Medicine and Pediatrics at the Medical College of Wisconsin, followed by Allergy/Immunology Fellowship at The Ohio State University/Nationwide Children’s Hospital.  She currently serves as chair of the ACAAI Population Health Committee.
      Disclosures: Nothing to disclose

      Niraj C. Patel, MD, MS | is an Associate Professor of Pediatrics, Allergy and Immunology. He is an immunologist who treats primary immunodeficiencies in children and adults. His patient population includes those with recurrent infections and fevers, drug allergies, and secondary immunodeficiencies. He is board certified with the American Board of Allergy & Immunology and American Board of Pediatric Infectious Diseases. He is currently a Pediatric Allergy and Immunology Specialist at Duke University Medical Center, Durham, NC.
      Disclosures: Speaker/Consultant - Amgen, Pharming Group, X4 Pharma; Speaker/Researcher - Takeda; Consultant - Janssen
       
      Moderator:
      Karla Adams, MD | is a Professor of Pediatrics and a practicing Allergist in San Antonio, Texas. She obtained her medical degree from the Uniformed Services University then completed a Pediatrics residency and Allergy and Immunology Fellowship at the San Antonio Uniformed Services Health Education Consortium in San Antonio, TX. She is currently the Program Director for the Allergy and Immunology Fellowship at Wilford Hall Ambulatory Surgical Center, San Antonio, TX.
      Disclosures: Nothing to disclose

      Available Credit

      • 1.00 AMA PRA Category 1 Credit™
      • 1.00 Attendance
      • 1.00 CBRN
      Please login or create an account to take this course.

      Vaccine Knowledge Booster 2025 Webinar Registration